Alventa Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 04-07-2024
- Paid Up Capital ₹ 3.51 M
as on 04-07-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 112.03%
(FY 2022)
- Profit 273.14%
(FY 2022)
- Ebitda -18966.50%
(FY 2022)
- Net Worth 264.52%
(FY 2022)
- Total Assets 25.38%
(FY 2022)
About Alventa Pharma
The Corporate was formerly known as Elder Labs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.51 M, as per Ministry of Corporate Affairs (MCA) records.
Rubi Mukhopadhyay, Biswajit Pan, Anand Parmanandka, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299WB2016PLC225674
- Company No.
225674
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Oct 2016
- Date of AGM
01 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Alventa Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rubi Mukhopadhyay  | Director | 04-Jun-2018 | Current |
| Biswajit Pan | Director | 07-Jun-2019 | Current |
| Anand Parmanandka | Additional Director | 29-Apr-2018 | Current |
| Ardhendu De | Nominee Director | 03-Aug-2023 | Current |
Financial Performance of Alventa Pharma.
Alventa Pharma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 112.03% increase. The company also saw a substantial improvement in profitability, with a 273.14% increase in profit. The company's net worth Soared by an impressive increase of 264.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alventa Pharma?
In 2020, Alventa Pharma had a promoter holding of 2.00% and a public holding of 98.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Aleris Pharmaceuticals LimitedActive 3 years 7 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Elder Laboratories LimitedActive 3 years 7 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Nicholas Pharma India LimitedActive 3 years 9 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Allenburys Pharma LimitedActive 4 years 2 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alventa Pharma?
Unlock and access historical data on people associated with Alventa Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alventa Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alventa Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
